Northern Trust
CAMP icon

Northern Trust’s CAMP4 Therapeutics CAMP Stock Holding History

Northern Trust’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$312K Sell
70,666
-3,843
-5% -$18.2K ﹤0.01% 3787
2025
Q4 		$457K Buy
74,509
+59,894
+410% +$255K ﹤0.01% 3687
2025
Q3 		$43.8K Hold
14,615
– – ﹤0.01% 4296
2025
Q2 		$21.2K Sell
14,615
-42,324
-74% -$84.2K ﹤0.01% 4329
2025
Q1 		$228K Buy
56,939
+5,079
+10% +$24.6K ﹤0.01% 3901
2024
Q4 		$271K Buy
+51,860
New +$426K ﹤0.01% 3878

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Northern Trust's CAMP Position: Q1 2026 in Review

Northern Trust reduced its CAMP4 Therapeutics (CAMP) stake by 5.2% in Q1 2026, selling an estimated $18.2K and leaving 70,666 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #3787.

Northern Trust first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. The position peaked at $457K in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Northern Trust held 70,666 shares of CAMP4 Therapeutics worth $312K as of Q1 2026.
  • Northern Trust sold 3,843 CAMP4 Therapeutics shares in Q1 2026, an estimated $18.2K.
  • CAMP4 Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3787 holding.
  • Northern Trust first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Northern Trust's CAMP4 Therapeutics position peaked at $457K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.